Values First Advisors’s BioLineRX BLRX Stock Holding History

Values First Advisors’s Portfolio BLRX Stock Details BLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-4,161	Closed	-$35.6K	–	188
2024 Q4	$35.6K	Sell	4,161 -777	-16%	-$11.5K	0.02%	201
2024 Q3	$106K	Sell	4,938 -156	-3%	-$4.29K	0.06%	179
2024 Q2	$116K	Buy	5,094 +3	+0.1%	+$81	0.07%	152
2024 Q1	$228K	Buy	5,091 +3,787	+290%	+$190K	0.13%	145
2023 Q4	$81.9K	Buy	1,304 +95	+8%	+$5.88K	0.05%	156
2023 Q3	$88K	Buy	+1,209	New	+$81.2K	0.06%	151

Other funds holding BLRX

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

NRG

Nemes Rush Group Novi, Michigan $1.21B AUM 33.22% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Values First Advisors's BLRX Position: Q1 2025 in Review

Values First Advisors sold out of BioLineRX (BLRX) in Q1 2025, closing a stake of 4,161 shares — an estimated $35.6K sold.

Values First Advisors first reported a position in BLRX in Q3 2023 and held it in 6 quarters. The position peaked at $228K in Q1 2024. 12 funds tracked by Wall St. Rank hold BLRX as of Q1 2025.

Values First Advisors reported no remaining BioLineRX position as of Q1 2025 after selling out during the quarter.
Values First Advisors sold 4,161 BioLineRX shares in Q1 2025, an estimated $35.6K.
Values First Advisors first reported a position in BioLineRX in Q3 2023 and held it in 6 quarters.
Values First Advisors's BioLineRX position peaked at $228K in Q1 2024.
12 funds tracked by Wall St. Rank held BioLineRX as of Q1 2025.

Based on Values First Advisors's 13F filing for Q1 2025, filed 30 Apr 2025.